Omeros (NASDAQ:OMER) Now Covered by Analysts at Rodman & Renshaw

Rodman & Renshaw initiated coverage on shares of Omeros (NASDAQ:OMER) in a report published on Thursday, MarketBeat reports. The firm issued a buy rating and a $9.00 price objective on the biopharmaceutical company’s stock.

Separately, StockNews.com lowered Omeros from a “hold” rating to a “sell” rating in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, one has given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $9.00.

Omeros Stock Down 2.9 %

OMER traded down $0.20 during trading on Thursday, hitting $6.75. The company’s stock had a trading volume of 1,931,790 shares, compared to its average volume of 466,108. The firm has a market capitalization of $391.14 million, a P/E ratio of -2.89 and a beta of 1.47. The stock’s fifty day moving average price is $4.08 and its 200-day moving average price is $4.07. Omeros has a twelve month low of $1.38 and a twelve month high of $7.51.

Hedge Funds Weigh In On Omeros

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in shares of Omeros by 2.6% during the 1st quarter. Vanguard Group Inc. now owns 3,250,284 shares of the biopharmaceutical company’s stock valued at $11,213,000 after acquiring an additional 81,348 shares during the last quarter. State Street Corp boosted its position in Omeros by 0.3% during the 3rd quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company’s stock worth $4,867,000 after acquiring an additional 3,839 shares during the period. Charles Schwab Investment Management Inc. increased its stake in shares of Omeros by 4.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 485,035 shares of the biopharmaceutical company’s stock worth $1,926,000 after purchasing an additional 18,454 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Omeros by 16.6% during the second quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company’s stock valued at $887,000 after purchasing an additional 31,081 shares during the period. Finally, Rhumbline Advisers raised its position in Omeros by 6.1% in the 2nd quarter. Rhumbline Advisers now owns 111,778 shares of the biopharmaceutical company’s stock valued at $454,000 after purchasing an additional 6,435 shares during the last quarter. Institutional investors and hedge funds own 48.79% of the company’s stock.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.